{"id":2473,"date":"2017-12-19T19:01:30","date_gmt":"2017-12-19T13:31:30","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=2473"},"modified":"2021-07-24T12:56:54","modified_gmt":"2021-07-24T07:26:54","slug":"notizia-61","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/notizia-61","title":{"rendered":"Regeneron\/Sanofi\u2019s PD-1 drug candidate; Zika targeting drugs and vaccines developments; CMO of Achillion will leave this month; Lincoln&#8217;s anti-malarial drug"},"content":{"rendered":"<p style=\"text-align: justify;\"><strong>Regeneron\/Sanofi\u2019s PD-1 drug candidate will be tested with ISA\u2019s HPV immunotherapy<\/strong><\/p>\n<p style=\"text-align: justify;\">Regeneron and Sanofi\u2019s PD-1 candidate cemiplimab is paired with Dutch biotech ISA Pharma\u2019s human papillomavirus (HPV) targeting drug for testing. The new drug is competing to become the sixth PD-1\/PD-L1 drug on the market. Joined with ISA\u2019s ISA101 vaccine candidate to cope with HPV-related cancers like cervical and head-and-neck cancer.<\/p>\n<p style=\"text-align: justify;\"><strong>Zika targeting drugs and vaccines development will be improved through new ideas<\/strong><\/p>\n<p style=\"text-align: justify;\">Scientists from Stanford have devised an approach that to fight Zika through a completely new approach by targeting a certain protein in the host cell further preventing the virus from replicating. It is one of two recent developments targeting Zika that could fuel ongoing efforts to prevent and treat the mosquito-borne virus.<\/p>\n<p style=\"text-align: justify;\"><strong>David Apelian chief medical officer of Achillion will leave this month <\/strong><\/p>\n<p style=\"text-align: justify;\">In a recent sec filing, the company has mentioned that David Apelian EVP and CMO of\u00a0Achillion has handed over his notice to leave the company by the end of this month i.e. Dec 28, 2017. In this brief update company has mentioned that he is leaving to \u201cpursue another professional opportunity\u201d. Company has started searching for a new CMO, with help from Russell Reynolds Associates.<\/p>\n<p style=\"text-align: justify;\"><strong>Lincoln Pharma has got the patent for its anti-malarial drug\u00a0<\/strong><\/p>\n<p style=\"text-align: justify;\">Lincoln Pharmaceuticals has recently announced that it has been awarded a patent for an anti-malarial drug in India. The patent has been awarded by the Indian government for an Arteether injection for the treatment of malaria according to a recent BSE filing.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Regeneron\/Sanofi\u2019s PD-1 drug candidate will be tested with ISA\u2019s HPV immunotherapy Regeneron and Sanofi\u2019s PD-1 candidate cemiplimab is paired with Dutch biotech ISA Pharma\u2019s human papillomavirus (HPV) targeting drug for testing. The new drug is competing to become the sixth PD-1\/PD-L1 drug on the market. Joined with ISA\u2019s ISA101 vaccine candidate to cope with HPV-related [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":2465,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[1252,1251,1168,1118,1771,204,1253,349,1250,17612,730,1230,1156,639,1249,504,533,610],"industry":[17225],"therapeutic_areas":[17231,17228],"class_list":["post-2473","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-achillion","tag-anti-malaria-drug","tag-business-consultancy","tag-business-research","tag-cancers","tag-delveinsight","tag-hpv","tag-latest-pharma-news","tag-lincoin-pharma","tag-lincoln-pharma","tag-notizia","tag-pharma-consultancy","tag-pharma-consultant","tag-pharma-news","tag-pharma-update","tag-regeneron","tag-sanofi","tag-zika","industry-pharmaceutical","therapeutic_areas-infectious-diseases","therapeutic_areas-oncology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Regeneron\/Sanofi\u2019s PD-1; Zika target drugs; Achillions&#039;s CMO to quit<\/title>\n<meta name=\"description\" content=\"Regeneron and Sanofi\u2019s PD-1 candidate cemiplimab is paired with Dutch biotech ISA Pharma\u2019s human papillomavirus (HPV).......\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/notizia-61\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Regeneron\/Sanofi\u2019s PD-1; Zika target drugs; Achillions&#039;s CMO to quit\" \/>\n<meta property=\"og:description\" content=\"Regeneron and Sanofi\u2019s PD-1 candidate cemiplimab is paired with Dutch biotech ISA Pharma\u2019s human papillomavirus (HPV).......\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/notizia-61\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2017-12-19T13:31:30+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-07-24T07:26:54+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/12\/09021225\/Notizia.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1112\" \/>\n\t<meta property=\"og:image:height\" content=\"660\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Regeneron\/Sanofi\u2019s PD-1; Zika target drugs; Achillions's CMO to quit","description":"Regeneron and Sanofi\u2019s PD-1 candidate cemiplimab is paired with Dutch biotech ISA Pharma\u2019s human papillomavirus (HPV).......","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/notizia-61","og_locale":"en_US","og_type":"article","og_title":"Regeneron\/Sanofi\u2019s PD-1; Zika target drugs; Achillions's CMO to quit","og_description":"Regeneron and Sanofi\u2019s PD-1 candidate cemiplimab is paired with Dutch biotech ISA Pharma\u2019s human papillomavirus (HPV).......","og_url":"https:\/\/www.delveinsight.com\/blog\/notizia-61","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2017-12-19T13:31:30+00:00","article_modified_time":"2021-07-24T07:26:54+00:00","og_image":[{"width":1112,"height":660,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/12\/09021225\/Notizia.png","type":"image\/png"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/notizia-61","url":"https:\/\/www.delveinsight.com\/blog\/notizia-61","name":"Regeneron\/Sanofi\u2019s PD-1; Zika target drugs; Achillions's CMO to quit","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/notizia-61#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/notizia-61#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/12\/09021225\/Notizia.png","datePublished":"2017-12-19T13:31:30+00:00","dateModified":"2021-07-24T07:26:54+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"Regeneron and Sanofi\u2019s PD-1 candidate cemiplimab is paired with Dutch biotech ISA Pharma\u2019s human papillomavirus (HPV).......","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/notizia-61"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/notizia-61#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/12\/09021225\/Notizia.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/12\/09021225\/Notizia.png","width":1112,"height":660,"caption":"transthyretin amyloidosis"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/12\/09021225\/Notizia-300x178.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">achillion<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">anti-malaria drug<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">business consultancy<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">business research<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">cancers<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">DelveInsight<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">HPV<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Latest pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">lincoIn pharma<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Lincoln Pharma<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">pharma consultancy<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">pharma consultant<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">pharma update<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Regeneron<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Sanofi<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Zika<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">achillion<\/span>","<span class=\"advgb-post-tax-term\">anti-malaria drug<\/span>","<span class=\"advgb-post-tax-term\">business consultancy<\/span>","<span class=\"advgb-post-tax-term\">business research<\/span>","<span class=\"advgb-post-tax-term\">cancers<\/span>","<span class=\"advgb-post-tax-term\">DelveInsight<\/span>","<span class=\"advgb-post-tax-term\">HPV<\/span>","<span class=\"advgb-post-tax-term\">Latest pharma news<\/span>","<span class=\"advgb-post-tax-term\">lincoIn pharma<\/span>","<span class=\"advgb-post-tax-term\">Lincoln Pharma<\/span>","<span class=\"advgb-post-tax-term\">Notizia<\/span>","<span class=\"advgb-post-tax-term\">pharma consultancy<\/span>","<span class=\"advgb-post-tax-term\">pharma consultant<\/span>","<span class=\"advgb-post-tax-term\">pharma news<\/span>","<span class=\"advgb-post-tax-term\">pharma update<\/span>","<span class=\"advgb-post-tax-term\">Regeneron<\/span>","<span class=\"advgb-post-tax-term\">Sanofi<\/span>","<span class=\"advgb-post-tax-term\">Zika<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 8 years ago","modified":"Updated 5 years ago"},"absolute_dates":{"created":"Posted on Dec 19, 2017","modified":"Updated on Jul 24, 2021"},"absolute_dates_time":{"created":"Posted on Dec 19, 2017 7:01 pm","modified":"Updated on Jul 24, 2021 12:56 pm"},"featured_img_caption":"transthyretin amyloidosis","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/2473","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=2473"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/2473\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/2465"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=2473"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=2473"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=2473"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=2473"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=2473"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}